Yasunori Kaneko - Profile and Investment Details

Investor Profile

Yasunori Kaneko is a Venture Capital, Private Equity Firm based in Palo Alto, California, United States with a diverse investment portfolio that includes companies such as Tetraphase Pharmaceuticals, Avidia, Renovis, Eledon Pharmaceuticals, Sutro Biopharma, NovaCardia, Calibra Medical, Sunesis Pharmaceuticals, Concert Pharmaceuticals, Sirtris Pharmaceuticals, Tolerx, Dicerna Pharmaceuticals, Alteer, SI-BONE, ARCA biopharma, Proteon Therapeutics, KAI PharmaceuticalsRoche NimbleGen, Satiety, Xenoport, Collegium Pharmaceutical, Crescendo Bioscience, Genocea Biosciences, Sequel Pharmaceuticals, MAKO Surgical, iScribe, Receptor Biologix, Targanta Therapeutics, NovaSys, Guava Technologies, Calypso Medical, iBalance Medical, Applied Genetics Technologies Corporation, NOVASYS MEDICAL, Medivance, InteKrin, SpinalMotion, MAP Pharmaceuticals, . Over time, Yasunori Kaneko has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Yasunori Kaneko is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Genetics, Life Science, Information Technology (IT), Biotechnology, Genomics, Health Diagnostics, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Yasunori Kaneko, as their portfolio suggests a familiarity and interest in this area.

Understanding Yasunori Kaneko’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.